MPR Weekly Dose Podcast

MPR Weekly Dose Podcast #139

FDA pulls bebtelovimab EUA; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for Duchenne muscular dystrophy is accepted for Priority Review.

MPR Weekly Dose Podcast #138

Newly approved gynecologic cancer treatment; Zejula use restricted; intrauterine system use extended; a second insulin product is approved as a biosimilar to Lantus; and an FDA Advisory Committee take a vote on tenapanor.

MPR Weekly Dose Podcast #137

USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for investigational maternal RSV vaccine; updates to Clozapine REMS; FDA panel votes on investigational CNS/leptomeningeal metastasis treatment.

MPR Weekly Dose Podcast #136

Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.

MPR Weekly Dose Podcast #135

FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.

MPR Weekly Dose Podcast #134

Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.

MPR Weekly Dose Podcast #133

ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia.

MPR Weekly Dose Podcast #132

Warning about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrasting and a generic version of Tazorac. 

MPR Weekly Dose Podcast Episode #131

Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed in cognitive function.  

MPR Weekly Dose Podcast #130

This week, news of the FDA’s vote on AMX0035, the novel ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.

MPR Weekly Dose Podcast #129

Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; ‘rainbow fentanly’ targeting youth; and a device to treat chronic idiopathic constipation. 

MPR Weekly Dose Podcast #128

USPSTF recommendations on statin use for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkeypox through fecal microbiota transplantation.

MPR Weekly Dose Podcast #127

Novavax vaccine booster update; over-the-counter hearing aids; Priority Review for a castration-resistant prostate cancer combination treatment; first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.

MPR Weekly Dose Podcast #126

Emergency use authorization for intradermal administration of Jynneos; treatment approved for endometriosis pain; Amazon among the companies to receive a FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.

MPR Weekly Dose Podcast #125

A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA addresses the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall is expanded for an over-the-counter laxative.

MPR Weekly Dose Podcast #124

Emergency Use authorization for Novavax vaccine; the Pfizer-BioNTech vaccine gains adolescent approval; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.

MPR Weekly Dose Podcast #123

Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; Priority Review for early Alzheimer disease treatment; morphine tablets recalled.

MPR Weekly Dose Podcast #122

New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.

MPR Weekly Dose Podcast #121

Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.

MPR Weekly Dose Podcast #120

FDA panel vote on COVID-19 vaccines for young children; new drug approved to treat alopecia; Paxlovid tested in standard risk individuals.